NAT BME:使用开放性肺炎患者临床数据资源,通过深度学习预测COVID-19预后

2020-12-29 MedSci原创 MedSci原创

对COVID-19肺炎患者进行早期诊断并及时治疗,对于控制疫情,是非常重要的。然而,因为有限的医疗资源和大量感染的患者,这通常会导致医疗决策(如隔离或住院)的时间过长,这可能增加交叉感染的机会并影响预

COVID-19肺炎患者进行早期诊断并及时治疗,对于控制疫情,是非常重要的。然而,因为有限的医疗资源和大量感染的患者,这通常会导致医疗决策(如隔离或住院)的时间过长,这可能增加交叉感染的机会并影响预后效果。虽然COVID-19确诊依赖于通过逆转录定量PCR(RT-PCR)检测SARS-CoV-2 RNA,但该检测已被发现具有高特异性而且敏感性较低(Sn),报告的阳性率为38-57%。除了病原学实验室确认外,其他有助于确定COVID-19肺炎的关键诊断要素包括临床特征(CFs)和胸部计算机断层扫描(CT)图像。研究已经开始揭示相关的CFs,包括COVID-19的症状,如发烧、干咳、肌痛和呼吸短促。据报道,感染肺部的胸部CT影像学特征包括毛玻璃样混浊(GGO)和严重程度相关的强化。综合考虑上述诊断要素的特征,可以共同提高诊断的准确性和有效性。第一手CT和临床数据集的可用性对于指导临床决策、提供信息以加深对这种病毒感染的理解至关重要,为系统建模提供依据,以便于早期诊断和及时的医疗干预。实现这一目标的一个途径是建立一个开放获取和全面的资源,其中包括每个病人的胸部CT图像和CFs,以促进国际上共同努力,抗击COVID-19肺炎。

本文准备了两个队列,分别包括1170人和351人,分别是实验室确认的COVID-19患者、COVID-19阴性(对照)患者和疑似COVID-19患者,。1521例患者的临床发病率结果分为:(1)894例确诊为COVID-19,肺炎严重程度从轻度(24例,2.7%)、常规(596例,66.7%)、重度(202例,22.6%)到危重(72例,8.1%)不等;(2)328例COVID-19阴性(作为对照组处理)和(3)299例疑似COVID-19病例。并收集了他们相应的胸部CT图像,CFs和SARS-CoV-2实验室测试结果。

开发了一个以病人为中心的资源,命名为COVID-19的整合CT图像和CFs(iCTCF)来存档和共享丰富的数据。从1342名有胸部CT数据的受试者中导出了364357张JPEG格式的CT片,其中313名对照组的82239张(22.6%),21名轻度患者的3704张(1.0%),543名正常者的137512张(37.7%),56张,170例重症患者132例(15.4%)和35例重症患者8911例(2.4%),260例疑似COVID-19患者75859例(20.8%)。治愈病例共获得164998个CT切片,死者共获得4935个CT切片。CF资料分为基础资料、血常规、炎症试验、凝血试验、生化试验、免疫细胞分型、细胞因子分型、自身免疫试验、尿常规9大类130个类型。

使用队列1,整合了高度异质性的CT和CF数据集,用于无偏预测COVID-19患者(HUST-19)临床结果,包括发病(定义为轻度或常规型(I型)和重度或危重型(II型))和死亡率结果。对于发病结果,HUST-19曲线下面积(AUC)值分别为0.978、0.921和0.931,用于预测阴性病例(对照)、轻度或常规(I型)和重症或危重症(II型)患者。使用队列2作为验证数据集来评估HUST-19,其准确率一直令人满意。对于死亡率结果,本文将两个队列合并,得出预测死亡病例的AUC值为0.856。利用HUST-19对队列1中的299例疑似病例进行了回顾性分析,预测了207例潜在的Ⅰ型病例和71例潜在的Ⅱ型病例。

iCTCF和HUST-19适用于中国以外的地区。iCTCF数据库信息丰富、可靠,可作为COVID-19诊断和临床管理的重要资源。

Ning, W., Lei, S., Yang, J. et al. Open resource of clinical data from patients with pneumonia for the prediction of COVID-19 outcomes via deep learning. Nat Biomed Eng 4, 1197–1207 (2020). https://doi.org/10.1038/s41551-020-00633-5

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1884874, encodeId=70ed18848e4b6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Dec 29 11:24:13 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016757, encodeId=121b2016e57b6, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Sep 13 05:24:13 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911988, encodeId=c80391198853, content=很好,学到了很多东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab715446485, createdName=ms8000000881080338, createdTime=Tue Dec 29 22:24:47 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911930, encodeId=3047911930db, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92915448455, createdName=Theman, createdTime=Tue Dec 29 16:03:06 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911874, encodeId=974b9118e480, content=更新及时,很好的课程,继续努力💪, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Tue Dec 29 11:47:16 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911786, encodeId=2029911e86ff, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210717/f2d55872caa345f59eec6acd0dc9f4d1/de233fd323b94465b6c3aaf06d720434.jpg, createdBy=70232066622, createdName=1581ef306dm, createdTime=Tue Dec 29 01:22:36 CST 2020, time=2020-12-29, status=1, ipAttribution=)]
    2020-12-29 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1884874, encodeId=70ed18848e4b6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Dec 29 11:24:13 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016757, encodeId=121b2016e57b6, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Sep 13 05:24:13 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911988, encodeId=c80391198853, content=很好,学到了很多东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab715446485, createdName=ms8000000881080338, createdTime=Tue Dec 29 22:24:47 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911930, encodeId=3047911930db, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92915448455, createdName=Theman, createdTime=Tue Dec 29 16:03:06 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911874, encodeId=974b9118e480, content=更新及时,很好的课程,继续努力💪, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Tue Dec 29 11:47:16 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911786, encodeId=2029911e86ff, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210717/f2d55872caa345f59eec6acd0dc9f4d1/de233fd323b94465b6c3aaf06d720434.jpg, createdBy=70232066622, createdName=1581ef306dm, createdTime=Tue Dec 29 01:22:36 CST 2020, time=2020-12-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1884874, encodeId=70ed18848e4b6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Dec 29 11:24:13 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016757, encodeId=121b2016e57b6, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Sep 13 05:24:13 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911988, encodeId=c80391198853, content=很好,学到了很多东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab715446485, createdName=ms8000000881080338, createdTime=Tue Dec 29 22:24:47 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911930, encodeId=3047911930db, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92915448455, createdName=Theman, createdTime=Tue Dec 29 16:03:06 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911874, encodeId=974b9118e480, content=更新及时,很好的课程,继续努力💪, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Tue Dec 29 11:47:16 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911786, encodeId=2029911e86ff, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210717/f2d55872caa345f59eec6acd0dc9f4d1/de233fd323b94465b6c3aaf06d720434.jpg, createdBy=70232066622, createdName=1581ef306dm, createdTime=Tue Dec 29 01:22:36 CST 2020, time=2020-12-29, status=1, ipAttribution=)]
    2020-12-29 ms8000000881080338

    很好,学到了很多东西

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1884874, encodeId=70ed18848e4b6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Dec 29 11:24:13 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016757, encodeId=121b2016e57b6, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Sep 13 05:24:13 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911988, encodeId=c80391198853, content=很好,学到了很多东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab715446485, createdName=ms8000000881080338, createdTime=Tue Dec 29 22:24:47 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911930, encodeId=3047911930db, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92915448455, createdName=Theman, createdTime=Tue Dec 29 16:03:06 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911874, encodeId=974b9118e480, content=更新及时,很好的课程,继续努力💪, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Tue Dec 29 11:47:16 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911786, encodeId=2029911e86ff, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210717/f2d55872caa345f59eec6acd0dc9f4d1/de233fd323b94465b6c3aaf06d720434.jpg, createdBy=70232066622, createdName=1581ef306dm, createdTime=Tue Dec 29 01:22:36 CST 2020, time=2020-12-29, status=1, ipAttribution=)]
    2020-12-29 Theman

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1884874, encodeId=70ed18848e4b6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Dec 29 11:24:13 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016757, encodeId=121b2016e57b6, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Sep 13 05:24:13 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911988, encodeId=c80391198853, content=很好,学到了很多东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab715446485, createdName=ms8000000881080338, createdTime=Tue Dec 29 22:24:47 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911930, encodeId=3047911930db, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92915448455, createdName=Theman, createdTime=Tue Dec 29 16:03:06 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911874, encodeId=974b9118e480, content=更新及时,很好的课程,继续努力💪, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Tue Dec 29 11:47:16 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911786, encodeId=2029911e86ff, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210717/f2d55872caa345f59eec6acd0dc9f4d1/de233fd323b94465b6c3aaf06d720434.jpg, createdBy=70232066622, createdName=1581ef306dm, createdTime=Tue Dec 29 01:22:36 CST 2020, time=2020-12-29, status=1, ipAttribution=)]
    2020-12-29 phoebeyan520

    更新及时,很好的课程,继续努力💪

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1884874, encodeId=70ed18848e4b6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Dec 29 11:24:13 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016757, encodeId=121b2016e57b6, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Mon Sep 13 05:24:13 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911988, encodeId=c80391198853, content=很好,学到了很多东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab715446485, createdName=ms8000000881080338, createdTime=Tue Dec 29 22:24:47 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911930, encodeId=3047911930db, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92915448455, createdName=Theman, createdTime=Tue Dec 29 16:03:06 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911874, encodeId=974b9118e480, content=更新及时,很好的课程,继续努力💪, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Tue Dec 29 11:47:16 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=911786, encodeId=2029911e86ff, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210717/f2d55872caa345f59eec6acd0dc9f4d1/de233fd323b94465b6c3aaf06d720434.jpg, createdBy=70232066622, createdName=1581ef306dm, createdTime=Tue Dec 29 01:22:36 CST 2020, time=2020-12-29, status=1, ipAttribution=)]
    2020-12-29 1581ef306dm

    学习了

    0

相关资讯

JAMA Oncol:前列腺癌格林森分级的一种深度学习算法的开发和验证

在前列腺癌中,生物活检样本的格林森分级在确定治疗方案中具有关键的作用。然而,Gleason分级与大量观察者间的差异有关,因此需要决策支持工具来改善Gleason分级在常规临床实践中的可重复性。最近,有

Nat Commun:深度学习模型分析人类复杂疾病的准确性

既往研究显示,通过全基因组关联研究(GWAS)分析鉴定出的疾病风险变异主要位于基因组的非编码区域中。因此,全基因组图谱的深度学习模型在预测DNA序列的调控作用方面存在着巨大的潜力。然而,目前深度学习尚

Heart:基于深度学习图像分析预测法洛四联症的预后

这项研究提供了使用外部影像数据集训练的机器学习算法自动估算ToF患者预后有效性的数据。

Eur Urol:深度学习预测肌层浸润膀胱癌分子亚型

肌层浸润膀胱癌(MIBC)是第二大常见的泌尿生殖系恶性肿瘤,并且与具有高的发病率和死亡率。近期研究人员鉴定了MIBC的分子亚型,这具有重要的临床应用。

Nature Machine Intelligence:深度学习实现前列腺癌病理的高准度分析

深度学习(DL)是实现组织结构数字病理识别和分类的有力方法。其在前列腺癌病理中的表现仍旧需要大量的调查。

Nat Commun:临床深度学习模型可用于血管造影图像中颅内动脉瘤的检测

颅内动脉瘤(IAs)作为一种相对常见的威胁生命的疾病,在一般人群中的患病率为3.2%,在自发性蛛网膜下腔出血(SAH)患者中高达85%。潜在IA的早期诊断既有利于临床治疗,也可以指导脑出血患者的预后。